High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: From morphology to proliferation and back

Endocrine Pathology

Volumn 25, Issue 2, 2014, Pages 193-198

  La Rosa, Stefano ^a   Sessa, Fausto ^b  

^a OSPEDALE DI CIRCOLO   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Classification; Large cell neuroendocrine carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumor; Small cell carcinoma

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER SIZE; CELL PROLIFERATION; DISEASE ASSOCIATION; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; MITOSIS RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; WORLD HEALTH ORGANIZATION; CARCINOMA, NEUROENDOCRINE; CLASSIFICATION; GASTROINTESTINAL NEOPLASMS; PANCREATIC NEOPLASMS; PATHOLOGY;

CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS;

EID: 84903648563     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-014-9316-9     Document Type: Article

References (40)

1. Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C (2005) Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clin Cancer Res 11:1765-1775 (Pubitemid 40471838)
2. Yachida S, Vakiani E, White CM, et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173-184
3. Yao JC, Shah MH, Ito T, et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523
4. Fazio N, Scarpa A, Falconi M (2014) Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. Curr Med Chem 21:1017-1025
5. Moertel C, Kvols L, O'Connel M, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232
6. Smith J, Reidy-Lagunes D (2013) The management of extrapulmonary poorly differentiated (high grade) neuroendocrine carcinomas. Semin Oncol 40:100-108
7. La Rosa S, Marando A, Sessa F, Capella C (2012) Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers 4:11-30
8. Solcia E, Klöppel G, Sobin LH, et al (2000) Histological typing of endocrine tumours. WHO International Histological Classification of Tumours, 2nd Edition. Springer, Berlin
9. Rindi G, Arnold R, Bosman FT, et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumours of the digestive system. IARC Press, Lyon, pp 13-14
10. Jiang SX,Mikami T, Umezawa A, SaegusaM, Kameya T, Okayasu I (2006) Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 30:945-953 (Pubitemid 44264942)
11. Shia J, Tang LH,WeiserMR, et al (2008) Is nonsmall cell type highgrade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 32:719-731 (Pubitemid 351600819)
12. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C (2012) Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 36:601-611
13. Basturk O, Hruban RH, Adsay NV, et al (2014) Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 38:437-447
14. Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, Scagliotti GV, Papotti M (2014) Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Hum Pathol 45:665-673
15. Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G (2011) Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis 43(Suppl 4):S356-S360
16. Corrin B, Gilby ED, Jones NF, Patrick J (1973) Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer 31:1523-1527
17. Wick MR (2000) Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 17:194-203
18. DeLellis RA, Shin SJ, Treaba DO (2010) Immunohistology of endocrine tumors. In: Dabbs DJ (ed). Diagnostic Immunohistochemistry: Theranostic and genomic applications. Saunders Elsevier, Philadelphia, pp 291-339
19. Barbareschi M, Roldo C, Zamboni G, Capelli P, Cavazza A, Macri E, Cangi MG, Chilosi M, Doglioni C (2004) CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 28:1169-1176 (Pubitemid 39121611)
20. La Rosa S, Rigoli E, Uccella S, Chiaravalli AM, Capella C (2004) CDX2 as a marker of intestinal EC-cells and related welldifferentiated endocrine tumors. Virchows Arch 445:248-254 (Pubitemid 39286892)
21. La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: Immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457:497-507
22. Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G (2011) Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 459:147-154
23. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A (2008) Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32:420-425 (Pubitemid 351398934)
24. Koo J, Zhou X, Moschiano E, De Peralta-VenturinaM, Mertens RB, Dhall D (2013) The immunohistochemical expression of Islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol 24:184-190
25. Agaimy A, Erlenbach-Wünsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Perren A, Klöppel G (2013) ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26:995-1003
26. La Rosa S,Marando A, Gatti G, Rapa I, Volante M, PapottiM, Sessa F, Capella C (2013) Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Hum Pathol 44:1391-1399
27. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 429:323-333 (Pubitemid 26421392)
28. Power DG, Asmis TR, Tang LH, Brown K, Kemeny NE (2011). High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol Suppl1:S169-S174
29. Akintola-Ogunremi O, Pfeifer JD, Tan BR, et al (2003) Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. Am J Surg Pathol 27:1551-1558 (Pubitemid 37486617)
30. Ishikubo T, Akagi K, Kurosumi M, Yamaguchi K, Fujimoto T, Sakamoto H, Tanaka Y, Ochiai A (2006) Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma. Jpn J Clin Oncol 36:494-498 (Pubitemid 44592677)
31. Gross DJ, Munter G, Bitan M, et al (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13:535-540 (Pubitemid 43886675)
32. Pages F, Galon J, Dieu-Nosjean MC Tartour E, Sautès-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093-1102
33. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virschows Arch 2006; 449:395-401 (Pubitemid 44451313)
34. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics of tumours of endocrine organs. World Health Organization Classification of Tumours. IARC Press, Lyon
35. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 42:1373-1384
36. Volante M, Daniele L, Asioli S et al (2013) Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. Am J Surg Pathol 37:606-612
37. Basturk O, Yang Z, Tang LH, et al (2013) Increased (>20%) Ki67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival. Mod Pathol 26(Suppl 2):423A
38. Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20:649-657
39. Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol Suppl 7:vii65-71
40. SorbyeH,Welin S, LangerSW, et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152-160